Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Return on Capital Employed (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Return on Capital Employed for 6 consecutive years, with 0.57% as the latest value for Q3 2024.

  • On a quarterly basis, Return on Capital Employed rose 4.0% to 0.57% in Q3 2024 year-over-year; TTM through Sep 2024 was 0.57%, a 4.0% increase, with the full-year FY2023 number at 0.58%, down 19.0% from a year prior.
  • Return on Capital Employed was 0.57% for Q3 2024 at Actinium Pharmaceuticals, up from 0.59% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.18% in Q2 2021 to a low of 0.68% in Q4 2023.
  • A 4-year average of 0.49% and a median of 0.54% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: rose 23bps in 2022, then plummeted -35bps in 2023.
  • Actinium Pharmaceuticals' Return on Capital Employed stood at 0.55% in 2021, then surged by 41bps to 0.33% in 2022, then crashed by -108bps to 0.68% in 2023, then rose by 15bps to 0.57% in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Return on Capital Employed are 0.57% (Q3 2024), 0.59% (Q2 2024), and 0.65% (Q1 2024).